Need professional-grade analysis? Visit stockanalysis.com
$24.04B
437.08
1,196
0.03%
BrightGene Bio Medical Technology C (688166) trades on SHG in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY57.20, down 0.26% from the previous close.
Over the past year, 688166 has traded between a low of CNY40.27 and a high of CNY116.49. The stock has gained 36.3% over this period. It is currently 50.9% below its 52-week high.
BrightGene Bio Medical Technology C has a market capitalization of $24.04B, with a price-to-earnings ratio of 437.08 and a dividend yield of 0.03%.
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, including metabolism, oncology, respiratory, immunosuppression, antiviral, antifungal, antitumor, cerebrovascular, iron supplement, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, digestion, and others. In addition, the company is involved in technology research and development; transfer of biomedical products; import, export, wholesale, and retail of medicines; production and operation of medical devices; and technical services. BrightGene Bio-Medical Technology Co., Ltd. was founded in 2001 and is based in Suzhou, China.
Side-by-side comparison against top Healthcare peers.